

MULTIPLE MYELOMA

15 December 2011 / Vol 480 / Issue No. 7377



COVER ART:
MATTHEW HOLLISTER

Editorial

Herb Brody, Michelle Grayson, Nick Haines

Art & Design

Wes Fernandes, Alisdair MacDonald, Andrea Duffy

Production

Donald McDonald, Emilia Orviss, Leonora Dawson-Bowling, Stephen Russell

Sponsorship

Reya Silao, Yvette Smith, Gerard Preston

Marketing

Elena Woodstock, Hannah Phipps

Project Managers

Helen Anthony, Claudia Deasy

Art Director

Kelly Buckheit Krause

Magazine Editor

Tim Appenzeller

Editor-in-Chief

Philip Campbell

The bar for what constitutes good news about multiple myeloma is low. Physicians and researchers who study this deadly cancer of blood plasma cells can point to a doubling of the average survival time over the past decade or so. But make no mistake, a diagnosis of multiple myeloma is still horrible news: patients can expect to live a mere 7–8 years, during which time they'll probably find themselves hobbled as the disease damages their bones. The new classes of drugs that have extended life expectancy will inevitably lose their power as resistance develops, leaving only the option of an autologous stem-cell transplant — an arduous procedure that introduces risks of its own.

Yet through the lens of this rare form of cancer, researchers are gaining important insights into many other diseases. The progression of myeloma from a benign precursor state known as MGUS to the deadly malignancy depends on a complex of factors that are not yet fully understood. But it is clear that myeloma, with its epicentre in the bone marrow, depends strongly on the composition and behaviour of the cells and tissues around it. Studying this relationship has helped researchers learn more about the role of the tumour microenvironment in many other cancers. Similarly, multiple myeloma has provided an ideal opportunity to investigate the theory that the origin of malignancy lies in cancer stem cells that continue to produce new cancer cells even as drugs kill the old ones. And efforts to protect bones from the ravages of multiple myeloma have helped further the development of drugs that can serve those suffering from non-malignant bone disorders such as osteoporosis. Drugs and surgical techniques developed initially for multiple myeloma have revolutionized the way doctors treat other bone diseases.

We are pleased to acknowledge the financial support of Onyx Pharmaceuticals in producing this *Outlook*. As always, *Nature* takes sole responsibility for all editorial content.

Herb Brody

Supplements Editor

CONTENTS

S34 OVERVIEW

Multiple lines of attack

From basic research to treatment

S36 DIAGNOSTICS

The early bird

High-risk patients need prompt treatment

S38 ANIMAL MODELS

Towards a myeloma mouse

Can mice help us find a cure?

S40 DRUGS

More shots on target

The drugs are getting better

S43 TUMORIGENESIS

Testing ground for cancer stem cells

A controversial theory about cancer biology

S46 STEM CELLS

Transplants on trial

When should stem-cell transplants be given?

S48 MICROENVIRONMENT

Neighbourhood watch

Looking for clues in the bone marrow

S50 GENETICS

Profiling a shape-shifter

There are patterns in the genes

S52 IMAGING

Seeing is believing

Getting a clearer picture of myeloma

S54 AETIOLOGY

The path to disease

How a benign condition turns deadly

S56 ORTHOPAEDICS

Structural support

Myeloma helps researchers understand bones

S58 PERSPECTIVE

A model disease

A useful tool for cancer research

COLLECTION

S59 Setting the standard for newly diagnosed multiple myeloma

J. Laubach, P. G. Richardson & K. Anderson

S61 Initial genome sequencing and analysis of multiple myeloma

M. A. Chapman et al.

S67 Taking thalidomide out of rehab

R. J. Akhurst

S69 Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia

F. Lebrin et al.

Nature Outlooks are sponsored supplements that aim to stimulate interest and debate around a subject of interest to the sponsor, while satisfying the editorial values of *Nature* and our readers' expectations. The boundaries of sponsor involvement are clearly delineated in the *Nature Outlook* Editorial guidelines available at http://www.nature.com/advertising/resources/pdf/outlook_guidelines.pdf

CITING THE OUTLOOK

Cite as a supplement to *Nature*, for example, *Nature* Vol XXX, No. XXXX Suppl, Sxx–Sxx (2011). To cite previously published articles from the collection, please use the original citation, which can be found at the start of each article.

VISIT THE OUTLOOK ONLINE

The *Nature Outlook Multiple Myeloma* supplement can be found at http://www.nature.com/nature/outlook/multiple_myeloma

All featured articles will be freely available for 6 months.

SUBSCRIPTIONS AND CUSTOMER SERVICES

For UK/Europe (excluding Japan): Nature Publishing Group, Subscriptions, Brunel Road, Basingstoke, Hants, RG21 6XS, UK. Tel: +44 (0) 1256 329242. Subscriptions and customer services for Americas – including Canada, Latin America and the Caribbean: Nature Publishing Group, 75 Varick St, 9th floor, New York, NY 10013-1917, USA. Tel: +1 866 363 7860 (US/Canada) or +1 212 726 9223 (outside US/Canada). Japan/China/Korea: Nature Publishing Group — Asia-Pacific, Chiyoda Building 5-6th Floor, 2-37 Ichigaya Tamachi, Shinjuku-ku, Tokyo, 162-0843, Japan. Tel: +81 3 3267 8751.

CUSTOMER SERVICES

Feedback@nature.com
Copyright © 2011 Nature Publishing Group